Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Sunitinib
48%
Pediatric Oncology
42%
Pharmacokinetics
35%
Single nucleotide Polymorphism
35%
Metastatic Renal Cell Carcinoma (mRCC)
30%
Pediatric Cancer Patients
30%
Pharmacogenomics
30%
Cytochrome P450 2D6 (CYP2D6)
25%
Pharmacogenetics
21%
Genetic Variants
18%
Induced Toxicity
18%
Clinical Implementation
18%
Allele Carriers
18%
Clinical Pharmacogenetics Implementation Consortium
17%
Whole Genome Sequencing
17%
Overall Survival
15%
Genetic Polymorphism
15%
Progression-free Survival
15%
Tyrosine Kinase Inhibitor
15%
SU12662
15%
Association Analysis
15%
Inhibitor Formulations
15%
Age-appropriate Dosage Form
15%
Kinase Inhibitor
15%
Chemotherapy Toxicity
15%
Down Syndrome Cell Adhesion Molecule (DSCAM)
15%
PDLIM3
15%
5-hydroxytryptamine-3 Receptor Antagonist
15%
Methemoglobinemia
15%
Glucose-6-phosphate Dehydrogenase (G6PD)
15%
Acute Hemolytic Anemia
15%
Interleukin-13 (IL-13)
15%
Meta-analysis
15%
Annotation Tool
15%
Therapeutic Concentrations
15%
Analytical Validation
15%
Pharmacogenetic Testing
15%
Pharmacokinetic Variability
15%
Drug Use
15%
Developmental Changes
15%
Acute Lymphoblastic Leukemia
15%
Mitotane
15%
Sequence Specificity
15%
Pediatric Adrenocortical Tumors
15%
CYP2B6 Genotype
15%
CYP2D6 Genotype
15%
Metastatic Kidney Cancer
15%
Efficacy Outcomes
15%
Acute Lymphoblastic
15%
Pediatric Case
15%
Biochemistry, Genetics and Molecular Biology
Sunitinib
100%
Pediatrics
61%
Overall Survival
48%
Single-Nucleotide Polymorphism
48%
Progression Free Survival
37%
Cancer Cell
33%
Allele
31%
Pharmacogenetic Testing
30%
Pharmacogenetics
28%
Genetic Divergence
23%
CYP3A5
20%
CYP3A4
18%
High Risk Population
17%
Observational Study
17%
Whole Genome Sequencing
17%
Genetic Polymorphism
16%
Down Syndrome Cell Adhesion Molecule
15%
CTLA-4
15%
Pharmacogenomics
15%
Targeted Therapy
15%
Germline
11%
Germ Cell
11%
Genotyping
10%
Patient Coding
10%
Pharmacodynamics
9%
Tyrosine Kinase Inhibitor
8%
Anticancer
8%
Pharmacokinetics
8%
Drug Dose Reduction
6%
VEGF Receptors
6%
Digital Positive Youth Development
6%
Exome Sequencing
6%
Genetics
6%
Pazopanib
5%
Genome-Wide Association Study
5%
Medicine and Dentistry
Childhood Cancer
61%
Cancer Cell
42%
Pharmacogenetic Testing
30%
Biological Marker
29%
Pharmacogenetics
28%
Overall Survival
25%
Tyrosine-Kinase Inhibitor
23%
Sunitinib
22%
Targeted Therapy
18%
High Risk Population
17%
Observational Study
17%
Methemoglobinemia
15%
Glucose-6-Phosphate Dehydrogenase Deficiency
15%
Clear Cell
15%
Glucose 6 Phosphate Dehydrogenase
15%
Neoplasm
15%
Pharmacogenomics
15%
Invasive Procedure
15%
Cohort Studies
15%
Drug Dose Increase
15%
CTLA-4
15%
Kidney Metastasis
15%
Genetic Polymorphism
15%
Propofol
15%
Acute Lymphoblastic Leukemia
15%
Hemolytic Anemia
15%
Systematic Review
15%
Rasburicase
14%
Genetics
12%
Germ Cell
10%
Progression Free Survival
9%
Pharmacokinetics
9%
Hemolysis
9%
Exome Sequencing
8%
Pharmacodynamics
6%
Single Nucleotide Polymorphism
6%
Tumor Lysis Syndrome
6%
Treatment Outcome
6%
Whole Genome Sequencing
5%
Supportive Care
5%
Prognostication
5%
